- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 16 Jul 21 EFFECT Notice of effectiveness
- 15 Jul 21 424B3 Prospectus supplement
- 13 Jul 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
1 Jul 21 S-4 Registration of securities issued in business combination transactions
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Registration Statement of Acasti Pharma Inc. on Form S-4 to be filed on or about June 30, 2021 of our reports dated March 26, 2021, on our audits of the financial statements of Grace Therapeutics, Inc. (the “Company”) as of December 31, 2020, 2019 and for each of the years then ended, and March 2, 2021 on our audit of the financial statements of Grace Therapeutics, Inc. as of December 31, 2018 and for the year ended. Our reports include an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern. We also consent to the reference to our firm under the caption “Experts” in this Registration Statement.
/s/ EisnerAmper LLP
EISNERAMPER LLP
Iselin, New Jersey
June 30, 2021